TruScreen Group (TRU) Investor presentation summary

Company overview and leadership

• Listed on ASX and NZX with a market cap of NZD $19.34m and FY24 sales exceeding NZD $2m.

• Manufactures and markets an AI-enabled cervical cancer screening device, TruScreen Ultra.

• Leadership team includes experienced executives and medical advisors with backgrounds in healthcare, finance, and medical device engineering.

Technology and clinical performance

• TruScreen Ultra is a real-time, AI-enabled handheld device using optical and electrical signals to detect pre-cancerous and cancerous cervical tissue.

• Device uses a single-use sensor (SUS) for each patient, ensuring safety and recurring revenue.

• Over 1 million women screened with no adverse events reported.

• Clinical trials with over 40,000 women show high sensitivity and specificity for CIN2+ detection, comparable or superior to cytology.

Business model and financials

• Recurring revenue model based on consumable SUS sales for each screening.

• FY24 sales grew 27% YOY, SUS sales up 25%, and revenue increased 18%.

• EBITDA improved 15% YOY, net assets up 28%, and cash increased 23%.

• China SUS/device pull-through increased 40% YOY.